Refine
Year of publication
- 2023 (4) (remove)
Document Type
- Article (3)
- Doctoral Thesis (1)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Cardiovascular disease (1)
- Data and biomaterial collection (1)
- German Centre for Cardiovascular Research (1)
- Laborautomatisierung (1)
- Probentransport (1)
- Präanalytik (1)
- Research platform (1)
- Rohrpost (1)
- Standardisation (1)
- bone quality (1)
- estimated bone mineral density (1)
- self-report (1)
- sex-specific (1)
- sleep disorders (1)
Institute
- Institut für Klinische Chemie und Laboratoriumsmedizin (4) (remove)
Publisher
- Nature Publishing Group (1)
- Springer Nature (1)
- Wiley (1)
The German Centre for Cardiovascular Research (DZHK) is one of the German Centres for Health Research and aims to conduct early and guideline-relevant studies to develop new therapies and diagnostics that impact the lives of people with cardiovascular disease. Therefore, DZHK members designed a collaboratively organised and integrated research platform connecting all sites and partners. The overarching objectives of the research platform are the standardisation of prospective data and biological sample collections among all studies and the development of a sustainable centrally standardised storage in compliance with general legal regulations and the FAIR principles. The main elements of the DZHK infrastructure are web-based and central units for data management, LIMS, IDMS, and transfer office, embedded in a framework consisting of the DZHK Use and Access Policy, and the Ethics and Data Protection Concept. This framework is characterised by a modular design allowing a high standardisation across all studies. For studies that require even tighter criteria additional quality levels are defined. In addition, the Public Open Data strategy is an important focus of DZHK. The DZHK operates as one legal entity holding all rights of data and biological sample usage, according to the DZHK Use and Access Policy. All DZHK studies collect a basic set of data and biosamples, accompanied by specific clinical and imaging data and biobanking. The DZHK infrastructure was constructed by scientists with the focus on the needs of scientists conducting clinical studies. Through this, the DZHK enables the interdisciplinary and multiple use of data and biological samples by scientists inside and outside the DZHK. So far, 27 DZHK studies recruited well over 11,200 participants suffering from major cardiovascular disorders such as myocardial infarction or heart failure. Currently, data and samples of five DZHK studies of the DZHK Heart Bank can be applied for.
Poor sleep quality or sleep deprivation may be related to decreased bone mineral density. We aimed to assess whether associations of sleep characteristics and bone turnover or strength are present in adults from the general population and whether these are independent of common risk factors such as sex, age, and obesity. A total of 1037 participants from the Study of Health in Pomerania-TREND underwent laboratory-based polysomnography and quantitative ultrasound measurements at the heel. Of these participants, 804 completed standardised questionnaires to assess daytime sleepiness, insomnia, and sleep quality. Serum concentrations of two bone turnover markers, intact amino-terminal propeptide of type 1 procollagen (P1NP) and carboxy-terminal telopeptide of type 1 collagen (CTX) were measured. Cross-sectional associations of polysomnography variables (total sleep time, sleep efficiency, time spent wake after sleep onset, oxygen desaturation index, apnea–hypopnea index, and obstructive sleep apnea [OSA]), as well as sleep questionnaire scores with the bone turnover markers and the ultrasound-based stiffness index were assessed in linear regression models. In adjusted models, higher insomnia scores and lower sleep quality scores were related to a higher bone turnover in women but not in men. However, associations between polysomnography variables or questionnaire scores and the stiffness index were absent. Our study provides limited evidence for relationships between sleep characteristics and bone turnover and strength independent of common risk factors for OSA and osteoporosis. Nevertheless, women reporting poor sleep or insomnia in combination with risk factors for osteoporosis might benefit from an evaluation of bone health.
Aerocom® (Schwäbisch Gmünd, Deutschland) hat einen neuen Prototyp für Rohrpostsysteme entwickelt, der eine Transportkapazität von bis zu 9 Blutröhrchen hat. Diese werden beim Schließen des Deckels automatisch fixiert. In dieser Studie wurde der Einfluss des Transports auf die Qualität der Blutproben unter Verwendung des Prototyps im Vergleich zum Kuriertransport und der konventionellen Rohrpostkartusche (AD160, Aerocom®) untersucht.
Sets aus je drei Blutprobenröhrchen (1 Lithium-Heparin, 1 EDTA, 1 Natrium-Zitrat) von insgesamt 35 Probanden wurden zufällig auf die drei Transportmethoden Kurier, konventionelle Rohrpostkartusche und den Kartuschenprototypen verteilt. Nach dem Transport wurden 51 Messgrößen aus der klinischen Chemie, Hämatologie und Gerinnung ermittelt und miteinander verglichen.
Insgesamt zeigten 49 der 51 untersuchten Messgrößen eine gute Übereinstimmung zwischen den drei Transporttypen, insbesondere zwischen der konventionellen Kartusche und dem Kartuschenenprototyp. Im Blick auf die bekannten hämolysesensitiven Messgrößen zeigte Kalium keine statistisch signifikanten Diskrepanzen. Bei der Laktatdehydrogenase (LDH) und dem freien Hämoglobin (fHb) ergaben sich jedoch statistisch signifikante Unterschiede jeweils zwischen den Werten für Kurier und den beiden Rohrpostkartuschen, wobei diese Unterschiede aus klinischer Sicht zu vernachlässigen sind. So lag die mittlere Konzentration von fHb bei 0,29 g/L (18 µMol/L), 0,31 g/L (19 µMol/L) bzw. 0,32 g/L (20 µMol/L) für den Kuriertransport, die konventionelle Kartusche und den Kartuschenprototyp. Diese Unterschiede lassen sich analytisch nicht auflösen, da die minimale Differenz (MD) für fHb bei dieser Konzentration 0,052 g/L (3,23 µMol/L) beträgt.
Abschließend stellen wir fest, dass der Prototyp von Aerocom® für den Transport von diagnostischen Blutproben geeignet ist. Der gesamte Arbeitsablauf wird mithilfe dieses Prototyps maßgeblich verbessert, indem die Arbeitszeit auf der Station und im Labor verringert und gleichzeitig das Risiko für Hämolyse durch unzureichend oder falsch verpackte Proben minimiert wird.
Background and objectives
Various cross-sectional studies have observed an association between high circulating concentrations of the adipokine chemerin and an unfavorable metabolic profile. However, the prognostic value of chemerin for the risk of associated diseases and mortality was examined only in a few studies mostly using small and highly selected patient populations. We aimed to analyze the association between plasma chemerin concentrations and all-cause as well as cause-specific mortality in the general population.
Study design and methods
From the Study of Health in Pomerania (SHIP), participants of two independent cohorts (SHIP-START-1 [n = 3037], SHIP-TREND-0 [n = 4193]) were followed up for 15 and 9 years (median), respectively. The association between plasma chemerin and all-cause mortality was analyzed using multivariable Cox proportional hazard regression models. Additionally, cause-specific hazards for cardiovascular disease (CVD) and cancer mortality were modeled considering competing events.
Results
A total number of 507 and 208 deaths occurred during follow-up in SHIP-START-1 and SHIP-TREND-0, respectively. Multivariable regression analyses revealed a significant association between high plasma chemerin concentrations and greater overall mortality that was independent of major confounders. Each 30 ng/mL increase in chemerin was associated with a 17% higher risk of all-cause mortality (95%-confidence interval: 1.10–1.26). Cause-specific analyses further showed that the chemerin concentration was significantly associated with cancer mortality but not with CVD mortality.
Conclusion
The present study detected a positive association between plasma chemerin concentrations and all-cause mortality in a large population-based study sample. Cause-specific analyses have shown that chemerin is likely to play a decisive role in cancer-related deaths. However, a direct association with cardiovascular mortality could not be established.